Lv1
68 积分 2022-11-24 加入
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
1个月前
已完结
Myostatin-targeting antibody protects lean mass during incretin-induced weight loss
1个月前
已关闭
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
2个月前
已完结
Fibroblast Activation Protein Inhibitor Theranostics: Preclinical Considerations
2个月前
已关闭
Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis
2个月前
已完结
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
3个月前
已完结
Lecanemab: US Veterans Health Administration will cover cost of new Alzheimer’s drug
3个月前
已关闭
Tirzepatide Once Weekly for the Treatment of Obesity
4个月前
已完结
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
4个月前
已完结
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
5个月前
已完结
皖公网安备34019202002308
